Transmedics Group Inc (TMDX) gains 0.80% for July 21

Equities Staff  |

Transmedics Group Inc (NASDAQ: TMDX) shares gained 0.80%, or $0.25 per share, to close Wednesday at $31.35. After opening the day at $31.12, shares of Transmedics fluctuated between $32.48 and $30.48. 342,335 shares traded hands a decrease from their 30 day average of 497,041. Wednesday's activity brought Transmedics’s market cap to $866,008,857.

About Transmedics Group Inc

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Visit Transmedics Group Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Transmedics Group Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Transmedics Group Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content